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Abstract
Background: Uterine sarcomas are relatively rare tumors that account for approximately 1-3% of female genital
tract malignancies and between 4-9% of uterine cancers. Less than 8% of all cases are Mullerian adenosarcoma, a
distinctive uterine neoplasm characterized by a benign, but occasionally atypical, epithelial and a malignant, usually
low-grade, stromal component, both of which should be integral and neoplastic constituents of the tumor.
Mullerian adenosarcoma with sarcomatous overgrowth (MASO) is a very aggressive variant, associated with post-
operative recurrence, metastases, even when diagnosed in early stage.
Case Presentation: We present a fourth MASO case derived from uterine cervix in a 72-year-old woman with
metrorrhagia and a polypoid mass protruding through the cervical ostium. Total abdominal hysterectomy, bilateral
salpingo-oophorectomy, systematic pelvic lymph node dissection, omental biopsy and appendectomy were
performed. Surgery treatment was associated with adjuvant whole-pelvis radiation (45 Gy) and adjuvant
chemotherapy (cisplatin/ifosfamide). After nine months of follow up, the patient was free of tumor.
Conclusions: The rarity of MASO of the cervix involves a management difficult. Most authors recommend total
abdominal hysterectomy, usually accompanied by bilateral salpingo-oophorectomy. There is no common
agreement on staging by lymphadenectomy during primary surgery and adjuvant chemo-radio therapy.
Background
Uterine sarcomas are relatively rare tumors that account
for approximately 1-3% of female genital tract malignan-
cies and between 4-9% of uterine cancers[1-4]. Recently
a new FIGO classification and staging system [5] has
been specifically designed for uterine sarcomas to reflect
their different biologic behavior. Three new classifica-
tions have been developed: staging for leiomyosarcomas
and endometrial stromal sarcomas, staging for adenosar-
comas, staging for carcinosarcomas.
Particular interest in this treatment is covered by Mul-
lerian adenosarcoma, whose term was introduced by
Clement and Scully [6] in 1974 for a distinctive uterine
neoplasm characterized by a benign, but occasionally
atypical, epithelial and a malignant, albeit usually low-
grade, stromal component, both of which should be an
integral and neoplastic constituent of the tumor. This
tumor represents less than 8% of cases of uterine sarco-
mas[7-9]. Even rarer is the variant of Mullerian adeno-
sarcoma with sarcomatous overgrowth (MASO). It is
very aggressive and associated with post-operative recur-
rence, metastases, even when diagnosed and treated in
early stages[7,10,11]. The stromal component may
include only elements indige n o u st ou t e r u s( h o m o l o -
gous) or show differentiation toward elements not nor-
mally found in the uterus (heterologous), such as
cartilage, osteoid and striated muscle[12,13]. Among
these rhabdomyosarcoma is the most frequent. Adeno-
sarcoma arise most commonly from the endometrium,
sometimes including the lower uterine segment, but
some cases are situated in the endocervix and rare
examples arise within the myometrium from adenomyo-
sis. More rarely, adenosarcoma occurs in the vagina, in
the ovary, in the fallopian tube, arising from peritoneal
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any medium, provided the original work is properly cited.surface, or outside the female genital tract, for example
in the gut[14].
MASO of the uterine cervix is extremely rare. In this
report we present a MASO case, derived from uterine
cervix of a 72-year-old woman. To our knowledge it is
the fourth case reported in the English literature for its
location and the second MASO case of the cervix with
heterologous elements.
Case presentation
A 72-year-old Caucasian woman, Para 2012, in meno-
pause from the age of 51 years, who had never taken hor-
mone replacement therapy (HRT), presented with
metrorrhagia from about 20 days. In physiological ana-
mnesis the patient reported urinary incontinence and
nocturia, she denied taking oral contraceptive in fertile-
age. Pelvic examination revealed an elongated fleshy
polyp, protruding through the cervical ostium, probably
from endocervix. At the transvaginal ultrasonography
revealed a polypoid mass subverting completely the uter-
ine echostructure, with a thin residual posterior margin
of intact myometrium. Intense neovascularization. The
polypoid mass was removed for biopsy. Macroscopically,
the lesion was measured as 3 × 1, 5 × 1, 5 cm. Microsco-
pically, it was composed of a mucus-blood material
encompassing lymphocytes, histiocytes and atypical ele-
ments of neoplastic nature. T h e r ew e r em a r k e d l ya n a -
plastic focal areas composed of pleomorphic spindle cell
proliferation. About the immunophenotype, vimentin
was positive and desmin was positive in focal areas, but
keratin (MNF116) was negative. These findings deposed
for a mesenchymal neoplasm.
The patient has performed an abdominal Computed
Tomography contrast medium that shows a solid lesion
with axial diameter of about 6 cm, with inhomogeneous
densitometry, assuming contrast medium, surrounded
by a thicker rim, containing gas bubbles, present in the
pelvic, in continuity with the uterus, extending to the
cranio-caudal about 9 cm.
The serum concentrations of cancer markers CEA,
A F P ,C A1 9 - 9 ,C A1 2 5 ,H E 4 ,C A1 5 - 3a r ew i t h i nt h e
norm.
Cystoscopic examination revealed an urethra displaced
upwards, bladder trigone raised significantly compared
to standard as ab-extrinseco compression, but covered
with mucosa of normal appearance.
Total abdominal hysterectomy, bilateral salpingo-
oophorectomy, systematic pelvic lymph node dissection,
omental biopsy and appendectomy were performed. On
gross examination, a mass of about 8 cm deformed uter-
ine profile. Ovaries and other pelvic organs grossly
appeared normal. Gastrointestinal tract, paracolic gut-
ters, liver, spleen, kidneys, and the undersurface of the
diaphragm were free of lesions.
Surgery treatment was associated with adjuvant whole-
pelvis radiation (45 Gy) and adiuvant chemotherapy (cis-
platin/ifosfamide). After three month of follow up, the
patient was free of tumor.
On gross examination, a friable and polypoid lesion
arised from uterine cervix and involved the cervical-isth-
m i cm u c o s aa n dt h ee n d o m e t r i u m .Af o c a lc h r o n i c
ulceration of the head of the polyp was noted. The cut
surface of the tumor was fleshy and gelatinous. There
was focal myometrial invasion. On microscopic exami-
nation, the tumor was characterized by intimate admix-
ture of epithelial component and sarcomatous stromal
component. The epithelial component was minimal and
mostly without epithelial atypia; while the sarcomatous
component was clearly predominant (pure sarcoma:
70%), of high grade, with a high mitotic rate (10 MFs/10
HPFS). In addition, heterologous pure sarcomatous
areas were noted comprising of rhabdomyosarcoma.
There was no lymph node metastasis or lymphatic vas-
cular space invasion, but a non-neoplastic focal throm-
bosis of small blood vessels in the head of the polyp was
noted. Omentum and appendix were negative for tumor
localization. The cytoplasm of the stromal cells showed
a strong positive reaction for vimentin and desmin, but
was negative for smooth muscle actin. Also, tumor cells
were negative for b-HCG, estrogen and progesterone
receptors. Only the focal areas of stromal tissue were
positive for MYF 4 and also glands and rare isolated
cells were positive for Keratin (MNF116). (Figure 1)
Conclusions
Uterine adenosarcomas are relatively rare tumors, whose
incidence appears increased in the last years. This is
probably due both to a better understanding of different
Figure 1 Microscopic features and immunohistochemistry. 1.1
rhabdoid cells, 1.2 rhabdoid cells with necrosis, 1.3 mesenchymal
stomal cell differentiation, 1.4 vimentin immunohistochemistry, 1.5
desmin immunohistochemistry.
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cially with the development of the immunohistochemis-
try) and to a possible exposure to other different
predisposing factors, pelvic irradiation and the use of
tamoxifen for breast cancer[15].
Although the etiologic factors are still unknown, at
least three possible risk factors are currently under
discussion:
- Pelvic irradiation, exceptional cases have been
reported in patients with a history of previous pelvic
irradiation; [16]
- The hyperestrogenism, such as after prolonged unba-
lanced estrogen stimulation or long term oral contracep-
tive use; [17]
- Treatment with tamoxifen, a small series has been
reported after treatment with tamoxifen for breast can-
cer[18].
However, these may be coincidental associations and
there are no proven etiologic factors. Anyway, our
patient had none of these risk factors.
Uterine endometrial adenosarcomas were typically
found in post-menopausal women with the median age
at presentation of 58 years[7]. Compared with them,
cervical adenosarcomas tended to appear more often in
younger women with the average age at presentation of
31 years[19]. The most common presenting symptom is
abnormal vaginal bleeding (71%), spotting or menorrha-
gia or metrorrhagia, as in our patient. These tumors can
present as a pelvic mass (37%), uterine polyp (22%), or
an enlarged uterus (22%)[11]. Pain, foul smelling vaginal
discharge, or symptoms of pelvic pressure have also
been reported. In the largest published series of Muller-
ian Adenosarcomas of the cervix, the most common
finding is tissue protruding from the external cervical os
and the clinical impression is frequently of benign endo-
cervical polyps. A history of recurrent polyps on clinical
and pathologic examination is typical before MA is
finally diagnosed[7,19-24]. Typically, the glands are cys-
tic and the stroma concentrates around them forming
periglandular cuffs. The hystologic picture is reminiscent
o fap h y l l o d e st u m o ro ft h eb r e a s t [ 1 ] .U s i n gt h eW H O
definition, stromal mitotic activity of two or more per
HPFs is required for a diagnosis of adenosarcoma. [2,3]
but in practice the diagnosis is made with stromal mito-
tic activity less than this if the characteristic architecture
with periglandular cuffing is present, because the num-
ber of mitoses may be variable from area to area[14].
Adenosarcomas generally are low-grade neoplasms cap-
able of local recurrence after polypectomy or hysterect-
omy and less commonly distant metastasis. The two
most important adverse prognostic factors are deep
myometrial invasion, as a predictor of aggressive beha-
vior, and sarcomatous overgrowth, as a predictor of
poor prognosis[14,25]. Myometrial invasion is found in
15% of cases, but deep invasion in only 5%.[7] in 8-54%
of uterine and 30% of ovarian adenosarcomas, the sarco-
matous overgrouth, defined as the presence of pure sar-
coma, usually of high-grade and without a glandular
component, occupying at least 25% of the tumor, has
been reported[1]. The presence of heterologous ele-
ments, especially rhabdomyosarcoma, may represent a
more clinically aggressive tumor. Most cases of MASO
originate from the uterine corpus; while in the English
literature only three cases of the MASO of uterine cer-
vix have been described[26-28]. MASO of uterine cor-
pus has a highly aggressive malignant potential; but
aggressiveness of cervical MASO is uncertain because
they are extremely uncommon, since its cervical location
and the presence of heterologous elements are extre-
mely infrequent. Others unfavorable prognostic factors,
such as necrosis and extrauterine spread, have been
recognized in the MA of the uterus[26]. The main dif-
ferences between our case and other MASO cases
reported in English literature are the presence of focal
myometrial invasion in our case, and also the presence
of heterologous elements in our case as in Duggal et al’s
case[28].
About the immunophenotype, smooth muscle actin
and desmin may also be positive. In areas of high-
grade sarcoma and of sarcomatous overgrowth, the
mesenchymal component exhibits a higher MIB1 pro-
liferation index and may be p53 positive. The immu-
nophenotype is similar to that of an undifferentiated
uterine sarcoma with usually loss of expression of the
cell differentiation markers estrogen receptor, proges-
terone receptor and CD10[29,30]. Area of rhabdo-
myosarcoma express desmin and skeletal muscle
markers, myogenin and myoD1. In adenosarcoma
with sarcomatous overgrowth, the mesenchymal com-
ponent may be DNA aneuploid whereas in adenosar-
comas without sarcomatous overgrowth, it is usually
DNA diploid [31].
The differential diagnosis of MASO of the uterine cer-
vix should be made with caution. It includes benign
lesions (such as adenofibroma, endocervical polyp, ade-
nomyoma of the cervix) and malignant lesions (such as
malignant mixed mullerian tumors, embryonal rhabdo-
myosarcoma). MA can be easily distinguished from ade-
nofibroma (both epithelial and stromal components
benign) using the criteria defined as unique to adenosar-
coma such as, a marked degree of atypia of mesenchy-
mal cells, a histological malignant element, the presence
of myometrial invasion, and two or more mitotic figure
per 10 HPF[7,25]. However, these features are not
always present; thus, they are less applicable in the dis-
crimination of malignant degree. Some cases presented
with recurrent cervical polypoid lesions that were initi-
ally considered benign form, probably due to the
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normal areas adjacent to others with higher stromal
density, mitotic activity, and atypia. In those cases, most
patients subsequently return for recurrent endometrial
and endocervical polyps, which are reinterpreted as ade-
nosarcoma[7,19-23]. Adenomyomas can be distinguished
from adenosarcoma by the presence of well-defined
myomatous stroma. Malignant mixed mullerian tumors
(MMTs) are also biphasic lesions but both the stroma
and the epithelium are malignant. In accord to the
uterine MASO, MMTs behave aggressively and often
present with early recurrences and metastases[32,33].
Embryonal rhabdomyosarcoma (sarcoma botryoides),
the most common malignant tumor of the vagina in
infants and children, can occasionally present in the cer-
vix[34,35]. It consists of a polypoid growth with densely
cellular submucosal cambium layer and scattered rhab-
domyoblasts. The stroma is edematous, not fibrous and
the leaf-like pattern is absent. An important differentiat-
ing factor is the age at presentation, since embryonal
Table 1 Summary of MASO cases reported in English literature
Case Age Myometrial
invasion
Heterologous element Immunophenotype Lymphnode
metastasis/
vascular
invasion
Surgical
treatment
Adjuvant
treatment
Park H.M.
et al case
[3]
37 No No Vimentin:+ +
CD34: -
HMB-45: -
Desmin: -
Cytokeratin: -
S-100: -
CD99: -
SMA: +/-
No TAH +
BSO+
PLA
No
Comunoğlu
N. et al
case
[4]
60 No No Vimentin: ++
CD34: -
HMB-45: -
Cytokeratin: -
S-100: -
Pg: +
E: +
SMA and Desmin:
+ in sarcomatous stromal cell
No TAH +
BSO
No
Duggal R.
et al case
[5]
15 No Yes: chondrosarcoma, myxoid
liposarcoma, leiomyosarcoma,
rhabdomyosarcoma
Vimentin: + in low grade
sarcomatous areas; ++ in high
grade sarcomatous areas
CD10: + in low grade sarcomatous
areas
S-100: + in liposarcomatous areas
Pg: -
E: -
- TAH +
BSO +
O+P W
CHT
RT
Present
case
72 Yes: focal
invasion
Yes: rhabdomyosarcoma Vimentin: ++
keratin (MNF 16): +/-
MYF4: +/-
B-hCG:-
Pg: -
E: -
SMA: -
No TAH +
BSO+
PLA
O + PW +
A
CHT
RT
+: positive.
++: strongly positive.
-: negative.
+/-: positive in focal areas.
SMA: smooth muscular actin.
Pg: progestogen.
E: estrogen.
TAH: total abdominal hysterectomy.
BSO: bilateral salpingo-oophorectomy.
PLA: pelvic lymphadenectomy.
O: omentectomy.
PW: peritoneal washing.
A: appendectomy.
CHT: chemotherapy.
RT: radiotherapy.
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the cervix occurs in an older age group.
The relative rarity of cervical MASO made the assess-
ment of the most effective means of management diffi-
cult[9,19-23]. Most authors recommend total abdominal
hysterectomy, usually accompanied by bilateral salpingo-
oophorectomy[7,33]. Among gynecologists there is no
common consensus on the value of staging by lympha-
denectomy during primary surgery. In general, women
with superficial MA or MA confined to a cervical focal
area probably do not require radiation therapy, but
those with tumors invading more than halfway through
myometrium or with two or more unfavorable factors
have a high likelihood of recurrence and might benefit
from high-dose pelvic radiation with or without aggres-
sive chemotherapy[20,23]. Local excision has been cura-
tive in rare cases, and could be preferred especially in
young patients[7,23]. In their MASO case Park et al.
[26] performed total abdominal hysterectomy and bilat-
eral salpingo-oophorectomy with pelvic lymph node dis-
section. The patient didn’t receive adjuvant therapies
and underwent a regular follow-up. The patient was
clinically free of disease after 9 months of surgery.
Comunoğlu et al didn’t perform lymph node dissection
after total abdominal hysterectomy and bilateral sal-
pingo-oophorectomy and the patient was free of disease
for 14 months of surgery[27]. Duggal et al. performed
total abdominal hysterectomy with bilateral salpingo-
oophorectomy and omentectomy because of clinical and
histopathological features of the mass suggestive of a
possible cervical sarcoma. In addition, peritoneal wash-
ings were sent for cytological examination. Surgery
treatment was followed by six cycles of chemotherapy
and subsequent radiotherapy. After one year of follow
up, there was recurrence of disease and the patient died
[28]. About the management, the main difference
between our case and the previous MASO cases
reported in English literature is the surgical treatment
including pelvic lymph node dissection and adjuvant
chemo-radio therapy. Among gynecologists there is no
consense on the practical value of staging by lymphade-
nectomy during primary surgery. In uterine neoplasm
with a sarcomatous component the most important
prognostic factor generally is the stage[11,20,36-38]. The
lymphatic vascular space invasion seems a relevant prog-
nostic factor with an impact on overall survival and dis-
tant metastasis-free survival but only in the early stage
of the disease [9,39]
In conclusion, we present an extremely rare case of
cervical MASO, our knowledge the fourth case reported
in the English literature for its location and the second
MASO case of the cervix with heterologous elements.
(Table 1)
In uterus, adenosarcoma with sarcomatous overgrowth
are aggressive tumors frequently associated with post-
operative recurrence or metastases, and poor prognosis,
markedly contrasting with typical mullerian adenosar-
coma of the uterus. Myometrial invasion and heterolo-
gous elements seem to be principle prognostic factors
[26]. Aggressive behavior of MASO of the uterine cervix
is uncertain because they are extremely uncommon. The
rarity of the cases of cervical MASO and the variety of
the presenting symptoms (such as abnormal vaginal
bleeding, pelvic mass, abdominal pain, recurrent cervical
polyps), make difficult the differential diagnosis and so
the optimal therapy is uncertain. More case reports and
perspective studies are needed for determining the treat-
ment options for cervical MASO with heterologous
elements.
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